| Item Type | Name |
|
Concept
|
Thrombocythemia, Essential
|
|
Concept
|
Thrombocytosis
|
|
Academic Article
|
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
|
|
Academic Article
|
Experience with oral interferon-alpha in patients with essential thrombocythemia and polycythemia vera.
|
|
Academic Article
|
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.
|
|
Academic Article
|
Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
|
|
Academic Article
|
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.
|
|
Academic Article
|
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
|
|
Academic Article
|
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.
|
|
Academic Article
|
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a.
|
|
Academic Article
|
Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome.
|
|
Academic Article
|
High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
|
|
Academic Article
|
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
|
|
Academic Article
|
Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
|
|
Academic Article
|
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
|
|
Academic Article
|
Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations.
|
|
Academic Article
|
Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
|
|
Academic Article
|
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
|
|
Academic Article
|
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
|
|
Academic Article
|
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
|
|
Academic Article
|
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
|
|
Academic Article
|
JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.
|
|
Academic Article
|
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
|
|
Academic Article
|
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
|
|
Academic Article
|
Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience.
|
|
Academic Article
|
Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis.
|
|
Academic Article
|
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.
|
|
Academic Article
|
Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - Single center experience
|
|
Academic Article
|
Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.
|
|
Academic Article
|
Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
|
|
Academic Article
|
Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
|
|
Academic Article
|
Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?
|
|
Academic Article
|
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
|
|
Academic Article
|
Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
|
|
Academic Article
|
A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.
|
|
Academic Article
|
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
|
|
Academic Article
|
The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.
|
|
Academic Article
|
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
|
|
Academic Article
|
Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.
|
|
Academic Article
|
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
|
|
Academic Article
|
Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.
|
|
Academic Article
|
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.
|
|
Academic Article
|
A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
|
|
Academic Article
|
Developmental Therapeutics in Myeloproliferative Neoplasms.
|
|
Academic Article
|
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.
|
|
Academic Article
|
The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.
|
|
Academic Article
|
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
|
|
Academic Article
|
Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
|
|
Academic Article
|
Histomorphological responses after therapy with pegylated interferon a-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
|
|
Academic Article
|
SOHO State-of-the-Art Update and Next Questions: MPN.
|
|
Academic Article
|
Ruxolitinib for essential thrombocythemia?
|
|
Academic Article
|
Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non Nocere.
|
|
Academic Article
|
Emerging drugs for essential thrombocythemia.
|
|
Academic Article
|
The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
|
|
Academic Article
|
Updates in the management of polycythemia vera and essential thrombocythemia.
|
|
Academic Article
|
Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.
|
|
Academic Article
|
Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
|
|
Academic Article
|
Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.
|
|
Academic Article
|
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
|
|
Academic Article
|
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study.
|
|
Academic Article
|
Real-world patient characteristics and treatment patterns of ruxolitinib among patients with advanced essential thrombocythemia at community clinical practice.
|
|
Academic Article
|
Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.
|
|
Academic Article
|
Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.
|
|
Academic Article
|
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
|
|
Academic Article
|
Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
|
|
Academic Article
|
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.
|
|
Academic Article
|
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
|
|
Academic Article
|
A review of essential thrombocythemia and its complications.
|